Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats (Q51124369)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 July 2014

Language	Label	Description	Also known as
English	Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats	scientific article published on 30 July 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

author name string

H B Jia

1

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

J X Ma

2

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

X L Ma

3

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

J T Yu

4

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

R Feng

5

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

L Y Xu

6

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

J Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

D Xing

8

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

S W Zhu

9

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

Y Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

language of work or name

0 references

publication date

30 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

Osteoporosis International

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

25

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

12

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

2743-2754

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Intermittent cyclic mechanical tension-induced down-regulation of ectonucleotide pyrophosphatase phosphodiesterase 1 gene expression is mainly dependent on TGF-β1 in end-plate chondrocytes.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Parathyroid hormone as an anabolic skeletal therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Does osteocytic SOST suppression mediate PTH bone anabolism?

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Control of the SOST bone enhancer by PTH using MEF2 transcription factors

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Advantages of concurrent use of anabolic and antiresorptive agents over single use of these agents in increasing trabecular bone volume, connectivity, and biomechanical competence of rat vertebrae

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Estrogen Treatment Prevents Osteopenia and Depresses Bone Turnover in Ovariectomized Rats*

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Biodegradable composite scaffolds incorporating an intramedullary rod and delivering bone morphogenetic protein-2 for stabilization and bone regeneration in segmental long bone defects.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Sex steroids and the construction and conservation of the adult skeleton

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Myocyte enhancer factor 2 (MEF2).

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Osteoclast-derived activity in the coupling of bone formation to resorption.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Building bone with a SOST-PTH partnership

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2818-Y

21 January 2018

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17 beta-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sclerostin and Wnt signaling--the pathway to bone strength

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression profiling of cyclin B1 and D1 in cervical carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of serum sclerostin in healthy pre- and postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-014-2818-Y

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/25074352

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51124369&oldid=2268325586"